Abbott Laboratories

“Abbott combines solid healthcare diversification, strong device and diagnostics franchises, healthy cash generation, and manageable leverage, which keeps business risk relatively low. However, the company is not a top-tier compounder because parts of the portfolio remain slower growth and lower moat, management is good rather than exceptional, and the current valuation offers little margin of safety. The likely outcome is decent long-term returns, but not enough upside versus risk to justify a fresh high-conviction purchase today.”